2VIQ

Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

2VIQ の概要

• エントリーDOI: 10.2210/pdb2viq/pdb
• 関連するPDBエントリー: 1C5W 1C5X 1C5Y 1C5Z 1EJN 1F5L 1F92 1FV9 1GI7 1GI8 1GI9 1GJ7 1GJ8 1GJ9 1GJA 1GJB 1GJC 1GJD 1KDU 1LMW 1O3P 1O5A 1O5B 1O5C 1OWD 1OWE 1OWH 1OWI 1OWJ 1OWK 1SC8 1SQA 1SQO 1SQT 1U6Q 1VJ9 1VJA 1W0Z 1W10 1W11 1W12 1W13 1W14 2JDE 2VIN 2VIO 2VIP 2VIV 2VIW
• 分子名称: UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B, ACETATE ION, 4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide, ... (4 entities in total)
• 機能のキーワード: plasminogen activation, egf-like domain, blood coagulation, inhibitor, polymorphism, glycoprotein, fibrinolysis, kringle, zymogen, secreted, protease, hydrolase, urokinase-type plasminogen activator, pharmaceutical, serine protease, phosphorylation
• 由来する生物種: HOMO SAPIENS (HUMAN)
• 細胞内の位置: Secreted: P00749
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 28875.85

構造登録者

Frederickson, M.,Callaghan, O.,Chessari, G.,Congreve, M.,Cowan, S.R.,Matthews, J.E.,McMenamin, R.,Smith, D.,Vinkovic, M.,Wallis, N.G. (登録日: 2007-12-05, 公開日: 2008-01-22, 最終更新日: 2017-07-05)

• 主引用文献: Frederickson, M.,Callaghan, O.,Chessari, G.,Congreve, M.,Cowan, S.R.,Matthews, J.E.,Mcmenamin, R.,Smith, D.,Vinkovic, M.,Wallis, N.G.; Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator.; J.Med.Chem., 51:183-, 2008; PubMed: 18163548; DOI: 10.1021/JM701359Z

実験手法

X-RAY DIFFRACTION (2 Å)